These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

In the latest lawsuit, Apple was awarded $250 in damages – the statutory minimum, which was what the company sought in its ...

Medical-device maker said Joe Kiani, who previously informed the board of his decision to resign as chief executive, has been ...

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and ...

Needham analyst Michael Matson maintained a Hold rating on Masimo (MASI – Research Report) today. The company’s shares closed ...

Wells Fargo analyst Vik Chopra has assigned their bullish stance on MASI stock, giving a Buy rating yesterday. Vik Chopra has given his Buy ...

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 38%. Looking ahead, revenue ...

Penumbra and Inspire Medical Systems, providing valuable insights into their respective standings within the industry and their market positions and comparative performance. Masimo ranks at the ...

Vanderbilt University Medical Center is launching Masimo Radius VSM™ advanced wireless patient-worn vital signs monitoring ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.